Fig. 2From: A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancerMaximum reduction from baseline in sum of longest diameters (SLD) for target lesions. Blinded central radiology review data from individual patients in the primary efficacy populationBack to article page